ch.oddb.org
 
Apotheken | Hôpital | Interactions | LiMA | Médecin | Médicaments | Services | T. de l'Autorisation
Information professionnelle sur Kaliglutol®:Streuli Pharma AG
Information professionnelle complèteDDDimprimé 
Forme gal./Grpe.th.Composit.PropriétésPharm.cinét.Indic./emploiPosolog./mode d'empl.PrécautionsEffets indésir.
Interact.SurdosageRemarquesNum. SwissmedicMise à jour 
A12BA01 - Potassium ChlorideATC-DDD Version 2016. Source: WHO
A - Alimentary Tract and Metabolism
 
A12 - Mineral Supplements

This group contains mineral supplements used for treatment of mineral deficiency. All parenteral solutions of electrolytes are classified in B05B or in B05X. Magnesium carbonate used for treatment of mineral deficiency is classified in A02AA01.

A12B - Potassium
 
A12BA - Potassium

This group comprises preparations used as potassium supplements.
This group comprises also all combined potassium preparations used in the treatment of potassium deficiency conditions. Potassium citrate preparations indicated for e.g. treatment of renal tubular acidosis with calcium stones are classified here.
Small non-therapeutic amounts of potassium hydrogencarbonate are allowed at each level of plain potassium salts.
Potassium, combinations with other drugs, are classified at separate 5th levels using the corresponding 50-series. Combinations of different potassium salts are classified in A12BA30. Potassium salts in combination with other drugs are classified in A12BA51.
Diuretics and potassium in combination, see C03 - Diuretics.
See also B05 - Blood substitutes and perfusion solutions.

The DDDs are based on treatment of potassium deficiency and correspond to a potassium content of about 40 mmol potassium.

A12BA01 - Potassium Chloride
Concentr.Adm.RouteNote
 O 
2025 ©ywesee GmbH
Einstellungen | Aide | FAQ | Identification | Contact | Home